Unique Therapeutic Approach: REL-1017's novel mechanism of action as an NMDA receptor channel blocker offers a differentiated treatment paradigm for Major Depressive Disorder (MDD), potentially avoiding the side effects of other NMDA modulators.

Differentiated Safety Profile: Clinical trials suggest REL-1017 exhibits a favorable safety and tolerability profile, notably lacking the dissociative effects, sedation, and abuse potential seen with other NMDA receptor modulators.

Convenient Oral Dosing: As an oral medication, REL-1017 offers significant patient convenience compared to intravenous infusions or in-clinic intranasal treatments, potentially improving adherence and broader accessibility.